It has been documented that fratricide-resistant “off-the-shelf” CAR-T, known as UCART7, as a novel anti-CD7 CAR-T cell with a deficiency in TCR could exert robust cytotoxicity against CD7 expressing malignant cells in vitro and in vivo without GVHD development. This evidence concerns the gene CD7 and graft versus host disease.